CAS: 83602-39-5; (3R,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-((1R,2R,E)-1-Hydroxy-2-Methylhex-4-En-1-yl)-6,9,18,24-Tetraisobutyl-3,21-Diisopropyl-1,4,7,10,12,15,19,25,28-Nonamethyl-1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29

该化合物是一种属于免疫抑制剂类别的环虫化物,它源于Tolipolcaldium 充气管的真菌,在结构上与环球体A有关,主要与氨基酸成分不同.Cyclospolin H具有强效免疫抑制特性,使其在预防器官移植拒绝和治疗自发性疾病方面具有价值.它的行动机制包括抑制T细胞的激活和扩散,将其与环球菌捆绑在一起,从而抑制卡列素,这是T细胞信号路径中的关键酶.该物质是热液,影响其溶性和生物利用率,通常通过口服或静脉注射进行.由于它的免疫抑制作用,对病人的仔细监测对于管理潜在的副作用至关重要,包括感染和肾中毒的敏感性增加.总的来说,Cycloporin H在临床环境中,特别是在移植药物中,是一种重要的治疗剂.

结构式图片

欧盟法规

C&L通报

上下游产品

Cyclosporin A 79217-60-0

合成工艺路线路线简述

    7,8-Secocyclosporin-7-Carboxylic Acid置于4-二甲氨基吡啶,1-丙基磷酸酐体系中,用 二氯甲烷,乙酸乙酯 作为反应溶剂,化学反应 30.0H,以67%的收率获得产物环孢菌素 H
    参考文献:Expanding The Limits Of Isonitrile-Mediated Amidations: On The Remarkable Stereosubtleties Of Macrolactam Formation From Synthetic Seco-Cyclosporins
    标题:Expanding The Limits Of Isonitrile-Mediated Amidations: On The Remarkable Stereosubtleties Of Macrolactam Formation From Synthetic Seco-Cyclosporins
    摘要:The Scope Of Isonitrile-Mediated Amide Bond-Forming Reactions Is Further Explored In This Second-Generation Synthetic Approach To Cyclosporine (Cyclosporin A). Both Type I And Type Ii Amidations Are Utilized In This Effort,Allowing Access To Epimeric Cyclosporins A And H From A Single Precursor By Variation Of The Coupling Reagents. This Work Lends Deeper Insight Into The Relative Acylating Ability Of The Formimidate Carboxylate Mixed Anhydride (Fcma) Intermediate,While Shedding Light On The Far-Reaching Impact Of Remote Stereochemical Changes On The Effective Preorganization Of Seco-Cyclosporins.
    DOI:10.1021/ja2103372

    专利信息


    专利号:US-2012253007-A1
    优先权日:2011-03-28
    标题:Synthesis of Cyclosporin H
    发明人:WHITAKER CRAIG; CASPE STEPHANIE
    权利人:WHITAKER CRAIG; CASPE STEPHANIE; US GOV SEC NAVY
    摘要:A method of preparing purified cyclosporin H includes dissolving cyclosporin A in a first organic solvent and heating the first organic solvent in the presence of an acid catalyst; adding a base to the first organic solvent; recrystallizing cyclosporin H in a second solvent; and purifying the recrystallized cyclosporin H via chromatography to obtain purified cyclosporin H, while excluding recrystallizing the cyclosporin H in the presence of ether. In a further aspect, the method includes, after adding the base and before the recrystallizing, mixing the first organic solvent with a solvent more polar than the first organic solvent, separating the first organic solvent, and drying the first organic solvent. Cyclosporin H prepared as described herein was found to be biologically active, unlike that prepared using a previously-described method.

    专利号:US-5214130-A
    优先权日:1990-02-27
    标题 :Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
    发明人:PATCHETT ARTHUR A; TAUB DAVID; GOEGELMAN ROBERT T
    权利人:MERCK & CO INC
    摘要:New immunosuppressive cyclosporin analogs are disclosed consisting of [dehydro-Ala]8 cyclosporins and derived therefrom cyclosporins having a sulfur containing amino acid at position-8.

    专利号:US-12201669-B2
    优先权日:2021-03-11
    标 题:Small molecule suppressors of APOE gene expression and cerebral vascular amyloid pathology
    发明人:TSAI LI-HUEI; BLANCHARD JOEL
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:The present disclosure provides methods of inhibiting amyloid synthesis in a subject using small molecule inhibitors. The invention also includes methods of treating disease associated with amyloid synthesis, such as Alzheimer's disease. The small molecule inhibitors disclosed herein are compounds which are non-immunosuppressant cyclosporin including the pharmaceutically acceptable salts thereof.

    专利号:WO-2025079025-A1
    优先权日:2023-10-13
    标 题 :Ides-rapamycin conjugate in aav gene therapy
    发明人:KHAN TAYEBA; KENNISTON JON A; NATARAJAN MADHUSUDAN; PALLISER DEBORAH; LEE HONG MYUNG; RICE ELISE; WATTERS ALEXANDER L; PAPAIOANNOU NIKOLAOS
    权利人:TAKEDA PHARMACEUTICALS CO
    摘要:The present invention, provides among other things, a conjugate of an IgG degrading protease, e.g., Immunoglobulin G (IgG) degrading enzyme of the S. pyogenes (IdeS) protein or IgG-degrading enzyme/MAC-1 (IdeZ) protein, with an immunosuppressant molecule, e.g., rapamycin, for immunosuppression in applications such as gene therapy. The present disclosure also provides methods of synthesis of conjugates and methods of conjugation (i.e. sortase-mediated conjugation) of payloads to IdeS or IdeZ for use in such applications.

    专利号:RO-110144-B1
    优先权日:1992-02-13
    标题 :New cyclosporins, their method of synthesis and method of treatment and prevention of AIDS
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    福建科瑞药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.fjim.org.cn/
    电话: (0591)83470739👤
    📞福建科瑞药业有限公司 ⚠️参考联系方式

    销售电话:(0591)83470739
    邮箱:Lihua.Xiao@kerui.microport.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    1. Wenzel-Seifert, K., and Siefert, R. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L- leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E. Journal of Immunology 150, 4591-4599 (1993). 2. Yan, P., Nanamori, M., Sun, M., et al. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding. Journal of Immunology 177(10), 7050-7058 (2006). 3. Zhou, C., Zhou, Y., Wang, J., et al. V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins. Biochemistry Journal 451(2), 245-255 (2013). 4. Sherry, B., Yarlett, N., Strupp, A., et al. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proceedings of the National Academy of Sciences of the United States of America 89(8), 3511-3515 (1992). 5. Gschwendt, M., Kittstein, W., and Marks, F. The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2+/calmodulin dependent EF-2 phosphorylation in vitro. Biochemical and Biophysical Research Communications 150, 545-551 (1988).

    合成参考文献


    参考文献:10.1128/aac.41.9.1859
    摘要:Silverman JA, Hayes ML, Luft BJ, Joiner KA. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology. Antimicrob Agents Chemother. 1997 Sep;41(9):1859–66.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知